Welcome to the U.S. Hereditary Angioedema Association's website. We are a non-profit patient advocacy organization dedicated to expediting US approval of safer and more effective HAE therapies. In addition, we provide a wide range of services that include clinical trial placement, physician referrals, education, and individualized patient case management. Please click here and fill out a short form so we can provide you with the latest information regarding new HAE treatments and events sponsored by the HAE Association.

Please participate in the following survey:
 Insurance Survey



Clinical Trials
Bring much-needed HAE treatment to the US. Sign up to participate in the clinical trials

Register to be a member of our message forum and be a part of the HAEA online community.

Frequently Asked Questions About HAE
Everything you need to know about HAE diagnosis and treatment

Angioedema Table
Find out the difference between the different types of Angioedema

New Treatment Options
Learn about the ongoing clinical trials which will revolutionize the way HAE attacks are treated.

Physician Referral
Find a physician near you.

HAE Patient Email Support Group
Reach out to other HAE patients by subscribing to our message forum

Be part of our Volunteer Network!
Join our network of HAE patients who are motivated to help serve our patient community.

Jul 16, 2008 - InvestSource Inc.: Lev Pharmaceuticals Acquired by ViroPharma

Jul 15, 2008 - Jerini Receives European Commission Approval for FIRAZYR(R) (Icatibant) in the Treatment of HAE

Jul 11, 2008 - Pharming says ongoing open-label studies with Rhucin show positive results



HAEA News


Television Spot with Mother and Daughter HAE Patients



HAEA.org is supported by grants from the following biotechnology companies:
CSL Behring, Dyax Corporation, Genzyme Corporation, Jerini AG, Lev Pharmaceuticals, and Pharming NV